(-)-Blebbistatin

For research use only.

Catalog No.S7099 Synonyms: (S)-(-)-Blebbistatin

27 publications

(-)-Blebbistatin Chemical Structure

CAS No. 856925-71-8

(-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 220 In stock
USD 170 In stock
USD 370 In stock
USD 909 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's (-)-Blebbistatin has been cited by 27 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description (-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.
Targets
non-muscle myosin II ATPases [2]
(Cell-free assay)
0.5 μM-5 μM
In vitro

Blebbistatin, inhibits cytokinesis, alters the smooth movement of fish keratocytes and inhibits the spontaneous blebbing of a cell line lacking filamin. Blebbistatin is shown to inhibit the enzymatic activities of HMM fragments of nonmuscle myosin IIA, nonmuscle myosin IIB and of rabbit skeletal muscle myosin S1, but not smooth muscle myosin[1] Blebbistatin rapidly and reversibly inhibits Mg-ATPase activity and in vitro motility of non-muscle myosin IIA and IIB for several species, while poorly inhibiting smooth muscle myosin (IC50 = 80 μM). Blebbistatin potently inhibits Dictyostelium myosin II, but poorly inhibits Acanthamoeba myosin II. Blebbistatin does not inhibit representative myosin superfamily members from classes I, V, and X. [2] Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. Blebbistatin interferes neither with binding of myosin to actin nor with ATP-induced actomyosin dissociation. Instead, it blocks the myosin heads in a products complex with low actin affinity. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Rh41 Mnm5dWhVWyCjc4PhfS=> MlLHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> NUPT[41oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NH7EPWdyUFSVIHHzd4F6 NH34cpJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NYX1V|doRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MVPxTHRUKGG|c3H5 NUf6TmpieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
talin 1 / vinculin / paxillin; 

PubMed: 20308429     


Effects of myosin II inhibition on the interactions between vinculin, paxillin, and talin. IPs were performed from lysates of untreated control MEFs (control) or MEFs treated with 20 µM blebbistatin (Blebb) followed by immunoblot analysis. (A) IP with anti-vinculin (Vcl) antibodies, immunoblot with anti-vinculin and antipaxillin (Pxn; left), or anti–talin 1 (Tln; right) antibodies. (B) IP with antipaxillin antibodies and immunoblotting with antivinculin antibodies. White lines indicate that intervening lanes have been spliced out. (C) IP with anti–talin 1 antibodies and immunoblotting with antivinculin antibodies are shown.

paxillin / pY31 paxillin / pY397FAK / FAK; 

PubMed: 20308429     


(A) Immunoblot analysis of lysates of untreated (control) and cells treated with 20 µM blebbistatin (Blebb) or with 20 µM blebbistatin and 100 µM Na3VO4 using antibodies specific to paxillin (Pxn), pY31 paxillin, pY397FAK, or FAK.

PY epitopes / vinculin / paxillin; 

PubMed: 20308429     


(D) Antipaxillin IPs from lysates of untreated control or cells treated with either 20 µM blebbistatin, 100 µM Na3VO4, and 20 µM blebbistatin or 100 µM Na3VO4 alone followed by analysis by PAGE and immunoblotting with antibodies to vinculin, paxillin, or PY epitopes. (E–I) EGFP-conjugated paxillin (Pxn-GFP wt) or paxillin bearing mutations of tyrosines 31 and 118 to phenylalanines (Pxn Y31/118F) or glutamic acids (Pxn Y31/118E) were expressed in MEFs and either treated with 20 µM blebbistatin or not.

20308429
Growth inhibition assay
Cell viability; 

PubMed: 26733241     


(B) The time course of cell viability of isolated ventricular mouse myocytes in culture at 2, 24, and 48 h postplating (representative images). Supplementation with blebbistatin alone maintains cell viability to a greater extent that culture with BDM, blebbistatin and BDM in combination, or without any supplementation at both 24 and 48 h.

Cell death; 

PubMed: 26733241     


(C) Viability of myocytes assessed by PI staining at 6, 18, 24, and 48 h after plating. Supplementation with blebbistatin keeps a greater proportion of isolated mouse myocytes alive throughout the 48 h post isolation. *versus control P < 0.05.

26733241
Glycerol/urea gel electrophoresis
RLC phosphorylation; 

PubMed: 18701651     


A: cultures were incubated with 100 nM KT5926 (KT) for 60 min, and RLC phosphorylation was analyzed by glycerol/urea gel electrophoresis. Inhibition of MLCK caused a significant reduction in constitutive RLC phosphorylation. Monolayers preincubated with 100 nM KT5926 for 30 min and then treated with blebbistatin for an additional 30 min in the presence of inhibitor showed that MLCK was responsible for blebbistatin-induced RLC phosphorylation.

RLC phosphorylation; 

PubMed: 18701651     


B: effect of blebbistatin on MLCK catalytic activity. Both MLCK210 (lane 1) and MLCK155 (lane 4) catalyze RLC phosphorylation in the presence of Ca2+/CaM, whereas in the absence of Ca2+/CaM, no 32PO4 was incorporated into myosin II RLCs (lanes 2 and 5). Blebbistatin does not directly activate MLCK since incubation of either isoform of MLCK in phosphorylation buffer containing 50 μM blebbistatin in the absence of Ca2+/CaM resulted in no RLC phosphorylation (lanes 3 and 6). Blebbistatin does not inhibit MLCK activity in the presence of Ca2+/CaM (lanes 7 and 8). Lane 1, MLCK210 + Ca2+/CaM; lane 2, MLCK210 + EGTA; lane 3, MLCK210 + EGTA + 50 μM blebbistatin; lane 4, MLCK155 + Ca2+/CaM; lane 5, MLCK155 + EGTA; lane 6, MLCK155 + EGTA + 50 μM blebbistatin; lane 7, MLCK210 + Ca2+/CaM + 50 μM blebbistatin; lane 8, MLCK155 + Ca2+/CaM + 50 μM blebbistatin.

RLC phosphorylation; 

PubMed: 18701651     


C: effect of Ca2+ depletion on blebbistatin-induced RLC phosphorylation. For Ca2+ chelation, monolayers were preincubated for 1 h at room temperature in Ca2+-free HBSS containing 10 mM BAPTA-AM/1 μM thapsigargin. Cells were treated with blebbistatin for 30 min; samples were separated by glycerol/urea gel electrophoresis, transferred to nitrocellulose, and probed with anti-myosin RLC antibody. Ca2+ depletion prevents blebbistatin-induced RLC phosphorylation.

18701651
DIC image
Traction force of a palladin KD (Palld4) cell; 

PubMed: 27353427     


Palladin knockdown cells show more efficient recovery from Blebbistatin treatment. (A) DIC image of a palladin KD (Palld4) cell on a gel of intermediate stiffness (10–30 kPa range). Scale bar: 10 μm. (B) DIC image of the same cell as in A, 30 minutes after incubation in 15 μM blebbistatin. (C) DIC image of the cell 1 hour after washout from blebbistatin, showing recovery of cell morphology. (D) Traction force map of the cell in A showing robust generation of traction forces. (E) Traction force map of the cell in B, showing disappearance of traction forces upon blebbistatin addition. (F) Traction force map of the cell in C, showing recovery of traction forces 1 hour after Blebbistatin washout.

27353427
Immunofluorescence
GCs morphology; 

PubMed: 25598228     


The effect of Blebbistatin on GCs morphology. (a–b) Lamellipodium emerging from a DRG neuron in control condition and after treatment with 30 μM Blebbistatin, respectively. Note the 'filopodish' appearance of the lamellipodia after Blebbistatin treatment. (c) Immunostaining of DRG lamellipodium in control condition for actin (green) and tubulin (blue) staining. (d) As in (c) but in the presence of 30 μM Blebbistatin.

actin / NMIIA / tubulin; 

PubMed: 25598228     


(e) Immunostaining of a GC after Blebbistatin treatment for actin, NMIIA and tubulin and merge of the three staining. Arrows and arrowheads indicate filopodia with and without a clear staining for tubulin, respectively. (f) Immunostaining of a GC after Blebbistatin treatment for actin, NMIIB and tubulin and merge of the three staining.

VE-cadherin / F-actin; 

PubMed: 22090347     


(B) Immunofluorescence of VE-cadherin (red) and phalloidin staining of F-actin (green) following 30-min treatment with control inactive (+)-blebbistatin (left) or active (−)-blebbistatin (right) reveal reduced size of VE-cadherin puncta following myosin II inhibition. Insets are magnified with equal ratios relative to boxed regions in original image.

PY epitopes / actin; 

PubMed: 20308429     


Rho kinase–mediated myosin II activity and substrate stiffness slow MEF migration and increase adhesion size.(C) Immunolocalization of PY epitopes (P-Tyr) to visualize adhesions (green) and fluorescent phalloidin staining to visualize actin filaments (red) under the treatments as untreated cells (control), cells treated with 20 µM blebbistatin (Blebb) or 10 µM Y27632, or plated on 1.0 kPa compliant polyacrylamide substrates. Merged images are shown in the third column, and boxed regions are magnified in the fourth column. Bars: (third column) 10 µm; (fourth column) 2 µm.

PY epitopes / paxillin; 

PubMed: 20308429     


(A) Immunolocalization of paxillin (Pxn; red) and PY epitopes (P-Tyr; green) in untreated cells (control) or cells treated with 20 µM blebbistatin (Blebb). Merged images are shown in the third column, and boxed regions are magnified in the fourth column. Bars: (third column) 10 µm; (fourth column) 2 µm.

talin 1 / FAK / β1 integrin / zyxin / vinculin / α-actinin / paxillin; 

PubMed: 20308429     


(B) Immunolocalization of paxillin (red) with either (in green); talin 1 (Tln), FAK, β1 integrin (β1-Int), zyxin (Zyx), vinculin (Vcl), or α-actinin (Actn) in untreated control cells (left) or cells treated with 20 µM blebbistatin (right). Merged images are shown in the right column. Bar, 2 µm.

25598228 22090347 20308429

Protocol

Solubility (25°C)

In vitro DMSO 58 mg/mL (198.4 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 292.33
Formula

C18H16N2O2

CAS No. 856925-71-8
Storage 3 years -20°C(in the dark) powder
2 years -80°C(in the dark) in solvent
Synonyms (S)-(-)-Blebbistatin
Smiles CC1=CC2=C(C=C1)N=C3C(C2=O)(CCN3C4=CC=CC=C4)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy (-)-Blebbistatin | (-)-Blebbistatin supplier | purchase (-)-Blebbistatin | (-)-Blebbistatin cost | (-)-Blebbistatin manufacturer | order (-)-Blebbistatin | (-)-Blebbistatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID